# SALL4

## Overview
SALL4 is a gene that encodes the spalt-like transcription factor 4, a zinc finger transcription factor involved in various biological processes, including embryonic development and stem cell maintenance. The protein is characterized by multiple C2H2-type zinc finger domains, which facilitate its role as a transcriptional regulator by binding to specific DNA sequences. SALL4 is crucial for maintaining the pluripotency of embryonic stem cells and plays a significant role in normal hematopoiesis. It functions as both a transcriptional activator and repressor, interacting with complexes such as the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex to modulate gene expression. Clinically, SALL4 is implicated in several cancers, where its overexpression is associated with tumor proliferation and poor prognosis, making it a potential target for therapeutic intervention (Yang2018SALL4; Forghanifard2013Role; Lu2009Stem).

## Structure
SALL4 is a zinc finger transcription factor characterized by multiple C2H2-type zinc finger domains, which are crucial for its DNA binding capabilities. The protein's structure includes the zinc finger cluster 4 (ZFC4) domain, which is essential for recognizing AT-rich sequences in genomic DNA. This domain consists of two zinc fingers, ZFC4N and ZFC4C, that adopt a canonical β-β-α architecture and bind to the major groove of DNA. The ZFC4 domain specifically recognizes an AATA tetranucleotide through base-specific hydrogen bonding and van der Waals interactions, with key residues such as Asn912, Ile887, and Thr909 playing critical roles in these interactions (Watson2023Structure; Ru2022Structural).

Mutations in the zinc finger domains, such as H888R, R890W, and G911D, are associated with Okihiro syndrome and affect the protein's DNA binding affinity and localization (Watson2023Structure). SALL4 also interacts with the NuRD corepressor complex, influencing chromatin structure and gene expression (Ru2022Structural). The protein may undergo post-translational modifications like phosphorylation and has several splice variant isoforms, contributing to its functional diversity.

## Function
The SALL4 gene encodes a transcriptional and epigenetic regulator that plays a crucial role in maintaining the properties of embryonic stem cells (ESCs) and normal hematopoiesis. In healthy human cells, SALL4 expression is primarily found in bone marrow hematopoietic stem/progenitor cells (HSCs/HPCs) and is rapidly silenced as these cells differentiate into specific lineages (Yang2018SALL4). SALL4 is essential for ESC pluripotency and early embryonic development, acting as a core component of the 'stemness' regulatory circuit alongside factors like OCT4, SOX2, and NANOG (Yang2018SALL4; Tatetsu2016SALL4). 

SALL4 functions as both a transcriptional repressor and activator. It interacts with the NuRD complex, LSD1, and DNMTs to repress gene expression, such as the tumor suppressor gene PTEN, which is involved in regulating the AKT signaling pathway and cell growth (Tatetsu2016SALL4). SALL4 can also activate gene expression by recruiting the MLL complex, which is involved in the Wnt/β-catenin signaling pathway, important for development and cancer (Tatetsu2016SALL4). 

SALL4 is involved in the DNA damage response, where it stabilizes the Mre11-Rad50-Nbs1 complex, facilitating the activation of ATM-dependent responses to DNA double-strand breaks, highlighting its role in maintaining genomic stability (Tatetsu2016SALL4).

## Clinical Significance
The SALL4 gene is implicated in various cancers due to its role in promoting tumor proliferation, invasion, and metastasis. Overexpression of SALL4 is observed in several malignancies, including colorectal cancer, where it is associated with lymph node metastasis and poor differentiation of tumor cells (Forghanifard2013Role). In gastric cancer, SALL4 overexpression correlates with poor prognosis and is linked to the activation of the Wnt/β-catenin signaling pathway, contributing to cancer progression (Yang2021UpRegulation). Similarly, in breast cancer, SALL4 is overexpressed in early clinical stages and is essential for cancer cell proliferation (Watanabe2011SALL4).

In acute myeloid leukemia (AML), SALL4 is constitutively expressed and interacts with the Wnt/β-catenin pathway, contributing to leukemogenesis and the maintenance of leukemia stem cells (Ma2006SALL4). SALL4's involvement in the Notch signaling pathway also plays a role in cancer cell self-renewal and metastasis, particularly in esophageal squamous cell carcinoma (Sun2022SALL4). These findings highlight SALL4 as a potential diagnostic and therapeutic target in various cancers due to its significant role in tumor biology.

## Interactions
SALL4 is a transcription factor that interacts with various proteins and nucleic acids, playing a significant role in transcriptional regulation. It is known to associate with the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex, which includes components such as Mi-2b, MTA1, MTA2, p66, HDAC1, HDAC2, RbAP46, and RbAP48. This interaction is crucial for SALL4's function as a transcriptional repressor, as it facilitates nucleosome remodeling and histone deacetylation, leading to gene repression (Lu2009Stem).

SALL4 also interacts with the pluripotency factor Nanog in embryonic stem cells. This interaction involves the co-occupancy of enhancer regions of the Nanog and Sall4 genes, suggesting a regulatory circuit that maintains pluripotency and self-renewal. The N-terminal region of SALL4 is necessary for its interaction with Nanog, and both proteins co-occupy many genomic sites, indicating a cooperative role in transcription regulation (Wu2006Sall4).

In addition, SALL4 has been shown to bind to the promoter regions of the PTEN and SALL1 genes, repressing their transcription through its association with the NuRD complex. This binding is associated with decreased histone acetylation, further supporting its role in transcriptional repression (Lu2009Stem).


## References


[1. (Yang2018SALL4) Jianchang Yang. Sall4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis. Biomarker Research, January 2018. URL: http://dx.doi.org/10.1186/s40364-017-0115-6, doi:10.1186/s40364-017-0115-6. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40364-017-0115-6)

[2. (Watson2023Structure) James A Watson, Raphaël Pantier, Uma Jayachandran, Kashyap Chhatbar, Beatrice Alexander-Howden, Valdeko Kruusvee, Michal Prendecki, Adrian Bird, and Atlanta G Cook. Structure of sall4 zinc finger domain reveals link between at-rich dna binding and okihiro syndrome. Life Science Alliance, 6(3):e202201588, January 2023. URL: http://dx.doi.org/10.26508/lsa.202201588, doi:10.26508/lsa.202201588. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.26508/lsa.202201588)

[3. (Sun2022SALL4) Boshu Sun, Liangliang Xu, Wenhui Bi, and Wen-Bin Ou. Sall4 oncogenic function in cancers: mechanisms and therapeutic relevance. International Journal of Molecular Sciences, 23(4):2053, February 2022. URL: http://dx.doi.org/10.3390/ijms23042053, doi:10.3390/ijms23042053. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23042053)

[4. (Tatetsu2016SALL4) Hiro Tatetsu, Nikki R. Kong, Gao Chong, Giovanni Amabile, Daniel G. Tenen, and Li Chai. Sall4, the missing link between stem cells, development and cancer. Gene, 584(2):111–119, June 2016. URL: http://dx.doi.org/10.1016/j.gene.2016.02.019, doi:10.1016/j.gene.2016.02.019. This article has 102 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2016.02.019)

[5. (Forghanifard2013Role) Mohammad Mahdi Forghanifard, Meysam Moghbeli, Reza Raeisossadati, Alireza Tavassoli, Afsaneh Javdani Mallak, Samaneh Boroumand-Noughabi, and Mohammad Reza Abbaszadegan. Role of sall4 in the progression and metastasis of colorectal cancer. Journal of Biomedical Science, 20(1):6, 2013. URL: http://dx.doi.org/10.1186/1423-0127-20-6, doi:10.1186/1423-0127-20-6. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/1423-0127-20-6)

[6. (Lu2009Stem) Jiayun Lu, Hawon Jeong, Nikki Kong, Youyang Yang, John Carroll, Hongbo R. Luo, Leslie E. Silberstein, YupoMa, and Li Chai. Stem cell factor sall4 represses the transcriptions of pten and sall1 through an epigenetic repressor complex. PLoS ONE, 4(5):e5577, May 2009. URL: http://dx.doi.org/10.1371/journal.pone.0005577, doi:10.1371/journal.pone.0005577. This article has 125 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0005577)

[7. (Yang2021UpRegulation) Yang Yang, Xiaohong Wang, Yiqiang Liu, Ying Hu, Zhongwu Li, Ziyu Li, Zhaode Bu, Xiaojiang Wu, Lianhai Zhang, and Jiafu Ji. Up-regulation of sall4 is associated with survival and progression via putative wnt pathway in gastric cancer. Frontiers in Cell and Developmental Biology, February 2021. URL: http://dx.doi.org/10.3389/fcell.2021.600344, doi:10.3389/fcell.2021.600344. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.600344)

8. (Ru2022Structural) Structural insights into AT-rich DNA recognition by SALL family proteins. This article has 0 citations.

[9. (Ma2006SALL4) Y. Ma, W. Cui, J. Yang, J. Qu, C. Di, H. M. Amin, R. Lai, J. Ritz, D. S. Krause, and L. Chai. Sall4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (aml) and induces aml in transgenic mice. Blood, 108(8):2726–2735, October 2006. URL: http://dx.doi.org/10.1182/blood-2006-02-001594, doi:10.1182/blood-2006-02-001594. This article has 168 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2006-02-001594)

[10. (Wu2006Sall4) Qiang Wu, Xi Chen, Jinqiu Zhang, Yuin-Han Loh, Teck-Yew Low, Weiwei Zhang, Wensheng Zhang, Siu-Kwan Sze, Bing Lim, and Huck-Hui Ng. Sall4 interacts with nanog and co-occupies nanog genomic sites in embryonic stem cells. Journal of Biological Chemistry, 281(34):24090–24094, August 2006. URL: http://dx.doi.org/10.1074/jbc.c600122200, doi:10.1074/jbc.c600122200. This article has 223 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.c600122200)

[11. (Watanabe2011SALL4) Watanabe. Sall4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. International Journal of Oncology, April 2011. URL: http://dx.doi.org/10.3892/ijo.2011.929, doi:10.3892/ijo.2011.929. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2011.929)